Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Astegolimab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms ZARNIE
  • Sponsors Genentech
  • Most Recent Events

    • 27 Aug 2022 Status changed from active, no longer recruiting to discontinued, according to the results published in the Journal of Allergy and Clinical Immunology.
    • 27 Aug 2022 Primary endpoint (Percent Change of Total Eczema Area and Severity Index (EASI) Score) has not been met, according to Results published in the Journal of Allergy and Clinical Immunology.
    • 27 Aug 2022 Results assessing the efficacy, safety, and pharmacokinetics of astegolimab in patients with atopic dermatitis published in the Journal of Allergy and Clinical Immunology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top